{
    "ticker": "AVEM",
    "name": "Avenue Therapeutics, Inc.",
    "description": "Avenue Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with unmet medical needs. Founded in 2017, Avenue Therapeutics focuses on the development of intravenous (IV) formulations of established analgesics, with the aim of improving pain management in both hospital and outpatient settings. The company's lead product candidate, IV Tramadol, is designed to provide effective pain relief while minimizing the risk of addiction and abuse associated with opioid medications. Avenue Therapeutics is committed to advancing its pipeline through rigorous clinical trials to ensure safety and efficacy. The company's mission is to transform the way pain is managed in clinical environments, offering alternatives that can reduce reliance on traditional opioids. By leveraging its expertise in drug formulation and development, Avenue Therapeutics strives to bring forward solutions that enhance patient care and outcomes, all while adhering to the highest standards of regulatory compliance and scientific integrity.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2017",
    "website": "https://www.avenuetx.com",
    "ceo": "Lucy Lu",
    "social_media": {
        "twitter": "https://twitter.com/AvenueTx",
        "linkedin": "https://www.linkedin.com/company/avenue-therapeutics/"
    },
    "investor_relations": "https://investors.avenuetx.com",
    "key_executives": [
        {
            "name": "Lucy Lu",
            "position": "CEO"
        },
        {
            "name": "Kimberly D. Burch",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Analgesics",
            "products": [
                "IV Tramadol"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avenue Therapeutics, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Avenue Therapeutics, Inc. is dedicated to developing innovative therapies for pain management, focusing on IV formulations to improve patient outcomes.",
        "keywords": [
            "Avenue Therapeutics",
            "IV Tramadol",
            "Pain Management",
            "Biopharmaceuticals",
            "Analgesics"
        ]
    },
    "faq": [
        {
            "question": "What is Avenue Therapeutics known for?",
            "answer": "Avenue Therapeutics is known for developing IV formulations of analgesics, specifically IV Tramadol for pain management."
        },
        {
            "question": "Who is the CEO of Avenue Therapeutics?",
            "answer": "Lucy Lu is the CEO of Avenue Therapeutics, Inc."
        },
        {
            "question": "Where is Avenue Therapeutics headquartered?",
            "answer": "Avenue Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Avenue Therapeutics' lead product candidate?",
            "answer": "Avenue Therapeutics' lead product candidate is IV Tramadol."
        },
        {
            "question": "When was Avenue Therapeutics founded?",
            "answer": "Avenue Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "PTGX",
        "CERS",
        "MNKD",
        "RXDX"
    ],
    "related_stocks": [
        "NVS",
        "PFE",
        "BMY",
        "GILD"
    ]
}